DNTH Dianthus Therapeutics, Inc.
DNTH Dianthus Therapeutics, Inc.
Healthcare · Biotechnology
Market read
Scan convergence 1 scan as of 2026-08-17 1 bull converging
POC $37.35 · VWAP $65.99 · +74.1% vs 12m avg buyer
Insiders no data — outside the Form 4 poll — US-filer feed only (foreign filers report via MAR managers'-transactions notices)
Coverage
1 watchlist
DNTH Price Structure
Loading timeframes…
Peers
Every watchlist DNTH belongs to, members best 30-day change first — DNTH highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@monster-discoveries
Reported the quarter ending 2026-03-31: diluted EPS $-0.85, net income $-41M (SEC filing). Across the print the stock moved +1.2% (close before → first close after).
full note →Against street estimates
How DNTH's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.
News (last pull)
Headlines about DNTH from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.
pulled 58 days ago · Jun 21
- Dianthus sinks after Sanofi halts CIDP Phase 3 study
- Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Dianthus Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
- Dianthus Therapeutics to Participate in Two Investor Conferences
- Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 2026 Financial Results
DNTH research tape
37 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.